Mogamulizumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB12498 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | prostatic urethra urothelial carcinoma | KG + DL |
| 2 | kidney pelvis sarcomatoid transitional cell carcinoma | KG + DL |
| 3 | infiltrating bladder urothelial carcinoma sarcomatoid variant | KG + DL |
| 4 | renal pelvis papillary urothelial carcinoma | KG + DL |
| 5 | human herpesvirus 8-related tumor | KG + DL |
| 6 | ectomesenchymoma | KG + DL |
| 7 | malignant cutaneous granular cell skin tumor | KG + DL |
| 8 | middle ear neuroendocrine tumor | KG + DL |
| 9 | transitional cell carcinoma | KG + DL |
| 10 | Richter syndrome | KG + DL |
| 11 | metastatic neoplasm | KG + DL |
| 12 | malignant spiradenoma | KG + DL |
| 13 | HER2 positive breast carcinoma | KG + DL |
| 14 | cutaneous neuroendocrine carcinoma | KG + DL |
| 15 | normal breast-like subtype of breast carcinoma | KG + DL |
| 16 | progesterone-receptor positive breast cancer | KG + DL |
| 17 | progesterone-receptor negative breast cancer | KG + DL |
| 18 | breast tumor luminal A or B | KG + DL |
| 19 | liver neuroendocrine carcinoma | KG + DL |
| 20 | chromhidrosis | KG + DL |
| 21 | neoplastic disease or syndrome | KG + DL |
| 22 | polyclonal hypergammaglobulinemia | KG + DL |
| 23 | elephantiasis | KG + DL |
| 24 | recombinase activating gene 1 deficiency | KG + DL |
| 25 | CD4 deficiency | KG + DL |
| 26 | janus kinase-3 deficiency | KG + DL |
| 27 | recombinase activating gene 2 deficiency | KG + DL |
| 28 | glottis verrucous carcinoma | KG + DL |
| 29 | adrenal gland neuroblastoma | KG + DL |
| 30 | supraglottis verrucous carcinoma | KG + DL |
| 31 | indolent primary cutaneous T-cell lymphoma | KG + DL |
| 32 | T-B+ severe combined immunodeficiency | KG + DL |
| 33 | congenital combined immunodeficiency | KG + DL |
| 34 | uterine ligament adenocarcinoma | KG + DL |
| 35 | monoclonal paraproteinemia disease | KG + DL |
| 36 | complement deficiency | KG + DL |
| 37 | hidradenitis suppurativa | KG + DL |
| 38 | autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency | KG + DL |
| 39 | T-B- severe combined immunodeficiency | KG + DL |
| 40 | adenoid cystic carcinoma of the cervix uteri | KG + DL |
| 41 | uterine ligament serous adenocarcinoma | KG + DL |
| 42 | uterine ligament clear cell adenocarcinoma | KG + DL |
| 43 | signet ring cell variant cervical mucinous adenocarcinoma | KG + DL |
| 44 | endocervical carcinoma | KG + DL |
| 45 | uterine ligament mucinous adenocarcinoma | KG + DL |
| 46 | uterine ligament endometrioid adenocarcinoma | KG + DL |
| 47 | autosomal recessive lymphoproliferative disease | KG + DL |
| 48 | cervical adenosquamous carcinoma, glassy cell variant | KG + DL |
| 49 | endocervical type cervical mucinous adenocarcinoma | KG + DL |
| 50 | cervical mucinous adenocarcinoma, minimal deviation variant | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.